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INTRODUCTION
Melasma is a relatively common acquired symmetric hyper-
melanosis characterized by irregular light- to gray-brown ma-
cules and patches on sun-exposed areas (1). The most common
sites of involvement are the cheeks, forehead, upper lip, nose,
chin, and occasionally the forearms. Women are predominant-
ly affected, although it occasionally occurs in men. Melasma
occurs more commonly in Asian females, who account for one-
third of all the women in the world, than in Caucasians (2). 
Melasma is often distributed in one of three clinical pat-
terns, i.e., centrofacial, malar, and mandibular (3). Melasma
can also be divided into three types based on Wood's light
examination of the skin (1). The epidermal type has increased
melanin predominantly in the basal and suprabasal epider-
mis with accentuation by Wood's lamp. The dermal type has
melanin-laden macrophages in a perivascular distribution in
superficial and deep dermis, with no Wood's lamp accentu-
ation. The mixed type has both elements and appears as a
deep brown color, with Wood's lamp accentuation of only
the epidermal component. Various factors and causes are re-
sponsible for the pathogenesis of melasma, but a genetic pre-
disposition and solar radiation (UV radiation and visible light)
may be the two most important factors (4). 
Many therapeutic agents are available but are often unsat-
isfactory. At present hydroquinone is the most frequently used
for treatment and has been used alone and in combination
with corticosteroids and retinoic acid. Although the thera-
peutic effect of hydroquinone and retinoic acid in white and
black populations is well known, the effect among Asian pop-
ulations remains controversial (5-7). Higher concentrations
of hydroquinone increase not only the efficacy but also the
risk of untoward effects such as local irritation, contact der-
matitis, leukoderma, and occasionally ochronosis (7, 8). 
Thus, it is necessary to develop a more effective and less
irritating alternative treatment for better management of
melasma. Recently, it has been demonstrated that lincomycin
(LM) and linoleic acid (LA) can inhibit melanogenesis in in
vitro tests (9, 10). The purpose of this study was to investi-
gate the clinical efficacy of a new type of depigmenting agent,
topical application of LM and LA in combination with beta-
methasone valerate (BV), in Korean patients with melasma.
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Therapeutic Effect of Topical Application of Linoleic Acid and Lincomycin
in Combination with Betamethasone Valerate in Melasma Patients
Melasma is an acquired symmetric hypermelanosis characterized by irregular light-
to gray-brown macules and patches on sun-exposed areas. Many therapeutic
agents are available but are unsatisfactory. Recently, it has been demonstrated
that lincomycin (LM) and linoleic acid (LA) can inhibit melanogenesis in vitro. Our
purpose was to investigate the clinical efficacy of topical application of LM and
LA in combination with betamethasone valerate (BV) in melasma patients. Forty-
seven Korean female adults with clinically diagnosed melasma were enrolled in
a 6-week, double-blind, randomized clinical trial. Patients were treated with one
application of the vehicle (group A), 2% LM mixed with 0.05% BV (group B), or
2% LM mixed with 0.05% BV and 2% LA (group C) on the face every night. Deter-
mination of efficacy was based on the Melasma Area and Severity Index (MASI)
score and objective assessment (no effect, mild, moderate, or excellent) at inter-
vals of 2 weeks until the end of the study at 6 weeks. After 6 weeks, in comparison
with the pre-treatment MASI score, the average MASI score of group C decreased
to 68.9%, compared with 98% in group A (p<0.05) and 85.4% in group B. There
was no statistically significant difference between group A and group B. Seven
patients (43.7%) in group C revealed more than moderate improvement in objec-
tive assessment, compared with none in group A and two patients (12.5%) in
group B. There were no significant side effects. Topical application of linoleic acid
is considered to be effective in the treatment of melasma patients.
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Patients
The study included forty-seven Korean female adults (mean
age, 39.7 yr; range, 28-54) with a clinical diagnosis of melas-
ma. The subjects were randomized according to the order
they were enrolled into the study. Fifteen women (mean age,
39.7 yr; range, 31-52) were treated with the vehicle (group
A), sixteen (mean age, 39.8 yr; range, 28-47) with 2% LM
mixed with 0.05% BV (group B), and sixteen (mean age,
39.7 yr; range, 30-54) with 2% LM mixed with 0.05% BV
and 2% LA (group C). Prior to enrollment into the study,
none of the patients had used systemic or topical agents for at
least 1 month or 2 weeks, respectively. Patients with a histo-
ry of systemic illness and nursing or pregnant women were
excluded. All patients signed informed consent forms, ap-
proved by the institutional review board of Kyunghee Uni-
versity Hospital.
Treatment
Patients were instructed to apply the ointments to the pig-
mented areas of melasma lesions once daily at night. Patients
were advised to avoid sun-exposure and to use topical sun-
screen with sun protection factor of at least 15 during the
entire period of the treatment. This study started after the
summer months in all patients to avoid seasonal effect.
Clinical evaluation
At baseline, patients were questioned as to the age of onset
and family history of melasma. A clinical pattern of melasma
was assigned to each patient as centrofacial, malar, or mandi-
bular. Wood's light was used to determine the melasma type
as epidermal, dermal, or mixed. Determination of treatment
efficacy was based on the Melasma Area and Severity Index
(MASI) scores and objective assessment before treatment and
at intervals of 2 weeks until the end of 6 weeks' treatment.
The MASI system was developed by Kimbrough-Green et al.
(11) and calculated by the following equation.
MASI=0.3 (DF+HF) AF+0.3 (DMR+HMR) AMR+0.3
(DML+HML) AML+0.1 (DC+HC) AC
where D is darkness, H is homogenesity, A is area, F is fore-
head, MR is right malar, ML is left malar, C is chin, and the
values 0.3, 0.1=respective percentages of the total facial area.
Objective assessment was grouped into four categories: (1)
no effect (no visible changes of pigmentation); (2) mild (de-
crease of visible pigmentation, but there is still some visible
border); (3) moderate (marked decrease of visible pigmenta-
tion, but there is still some visible border); and (4) excellent
(a complete loss of visible abnormal pigmentation), which
was a modification of the objective assessment developed by
Jimbow (12). Two dermatologists evaluated the MASI score
and objective assessment for each photograph independently.
A mean of the MASI scores by each investigator was calcu-
lated. 
Photography
Color photographs of patients were taken at baseline and
after 2 and 6 weeks of treatment. The en face view and the left
and right oblique profiles of each patient were taken using a
reproduction ratio of 1:4.
A Nikon N70 camera with AF micro 105 mm lens, SB
23 Nikon flash with Canfield twin flash clinical system, and
two 5×2 ft umbrellas at 45-degree angle were used against
a green unit background. The photograph was taken in the
exactly same location each time, in a room without natural
light and lit only by fluorescent light on the ceiling. 
Statistical analysis
The non-parametric Wilcoxon rank sum test was used for
comparing clinical changes before and after 6 weeks of treat-
ment in MASI scores.
RESULTS
Forty-six patients completed the 6 weeks' treatment. One
patient in group C dropped out at 4 weeks because of non-
compliance. For patient demographics, see Table 1.
Clinical outcomes
After 6 weeks, in comparison with pre-treatment MASI
score, the average MASI score of group C decreased to 68.9%,
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Sex (M/F) 0/15 0/16 0/16
Age (yr) 39.7 (31-52) 39.8 (28-47) 39.7 (30-54)
Duration (yr) 8.5 (1-23) 6.8 (1-20) 10.2 (1-30)
<1 1 3 0
1-5 5 4 5
>5 9 9 11
Pattern (No.)
Malar 11 12 13
Centrofacial 4 4 3
Mandibular 0 0 0
Type (No.)
Epidermal 12 13 15
Mixed   3 3 1
Dermal 0 0 0
Family history (No.) 8 7 11
C (n=16) B (n=16) A (n=15) Variable
Table 1. Baseline characteristics of the melasma patients
A: Vehicle (Hydrophilic ointment); B: 2% Lincomycin+0.05% Betametha-
sone valerate; C: 2% Lincomycin+0.05% Betamethasone valerate+2%
Linoleic acid.compared with 98% in the vehicle-treated group A (p<0.05)
and 85.4% in group B. There was no statistically significant
difference between group A and group B (Fig. 1). As early
as 4 weeks after treatment in group C, four (25%) out of 16
patients showed an improvement of more than 50% of the
MASI score, none between 30 and 50%, 6 patients (37.5%)
between 10 and 29%, and 5 patients (31.3%) less than 10%
(data not shown). Patients with negative family history of
melasma showed a greater decrease of the MASI score com-
pared to those with positive family history in group C after
6 weeks of treatment (p<0.05) (Fig. 2). Patients with malar
pattern rather than centrofacial pattern revealed a greater de-
crease of the MASI score (Fig. 3). Patients with a shorter dura-
tion of melasma showed a greater decrease of the MASI score
(Fig. 4). Patients with the epidermal type revealed a greater
decrease of the MASI score (Fig. 5). However, the differences
shown in Fig. 3, 4, and 5 had no statistical significance. Results
of the objective assessment showed that seven patients (43.7
%) revealed more than moderate improvement in group C,
compared with two patients (12.5%) in group B and none
in group A (Fig. 6). Visible changes in the pigmentation of
melasma lesions could be seen as early as 2 weeks after topi-
cal application in group C. These patients in group C showed
an almost complete loss of melasma lesions after 6 weeks of
treatment (Fig. 7). 
Side effects
In all three groups, there were no significant side effects
during the entire period of treatment.
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Fig. 1. Changes of MASI score after 6 weeks of treatment.
A: Vehicle, B: 2% Lincomycin+0.05% Betamethasone valerate,
C: 2% Lincomycin+0.05% Betamethasone valerate+2% Linoleic
acid.
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Fig. 2. Changes of MASI score according to family history after 6
weeks of treatment.
A: Vehicle, B: 2% Lincomycin+0.05% Betamethasone valerate,
C: 2% Lincomycin+0.05% Betamethasone valerate+2% Linoleic
acid.
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Fig. 3. Changes of MASI score according to the pattern of melas-
ma after 6 weeks of treatment.
A: Vehicle, B: 2% Lincomycin+0.05% Betamethasone valerate,
C: 2% Lincomycin+0.05% Betamethasone valerate+2% Linoleic
acid.
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Fig. 4. Changes of MASI score according to the duration of melas-
ma after 6 weeks of treatment.
A: Vehicle, B: 2% Lincomycin+0.05% Betamethasone valerate,
C: 2% Lincomycin+0.05% Betamethasone valerate+2% Linoleic
acid.
>5 yrDISCUSSION
Lincomycin is elaborated by an actinomycete, Streptomyces
lincolensis; it was the first lincosamide antibiotic to be used
clinically. Lincomycin inhibits melanogenesis post-transcrip-
tionally and abrogates glucocorticoid-induced melanogenesis
on the transcriptional level in B16 melanoma cells (9). Fatty
acids have been shown to have remarkable regulatory effects
on melanogenesis in cultured B16F10 murine melanoma
cells. Unsaturated fatty acids, such as oleic acid, linoleic acid,
or  -linolenic acid, decrease melanin synthesis and tyrosinase
activity, while saturated fatty acids, such as palmitic acid or
stearic acid, increase them (10, 13). Linoleic acid (Fig. 8) is
a new bleaching agent and inhibits melanogenesis by accel-
eration of proteolytic degradation of tyrosinase in B16 murine
melanoma cells (14). It also accelerates the turn over of the
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Fig. 5. Changes of MASI score according to the type of melas-
ma after 6 weeks of treatment.
A: Vehicle, B: 2% Lincomycin+0.05% Betamethasone valerate,
C: 2% Lincomycin+0.05% Betamethasone valerate+2% Linoleic
acid.
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Fig. 6. Objective assessment of melasma patients after 6 weeks
of treatment.
A: Vehicle, B: 2% Lincomycin+0.05% Betamethasone valerate,
C: 2% Lincomycin+0.05% Betamethasone valerate+2% Linoleic
acid.
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Fig. 8. Chemical structure of linoleic acid.
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Fig. 7. Clinical photographs of responses of melasma to 2% lincomycin mixed with 0.05% betamethasone valerate and 2% linoleic acid.
A 35-yr-old woman with melasma (A) before treatment and (B) after 6 weeks of treatment. A 40-yr-old woman with melasma (C) before
treatment and (D) after 6 weeks of treatment.
A C B Dstratum corneum, which results in the faster desquamation
of melanin pigment from the epidermis. Topical application
of linoleic acid to UV-stimulated hyperpigmented dorsal skin
of brownish guinea pigs resulted in a pigment-lightening
effect (15).
There are still many arguments about the application of
topical steroids for the treatment of melasma. Kligman &
Willis (16) failed to find any beneficial effects from applying
topical corticosteroid alone. On the contrary, topical steroids
such as betamethasone, dexamethasone, clobetasol propionate,
and hydrocortisone can be effectively used for depigmentation
in combination with other depigmenting agents or alone (17-
19). Corticosteroids have been shown to exert their antimeta-
bolic effects by decreasing epidermal turnover (20). This in
turn may also affect the melanocyte by decreasing its secre-
tory function. Fluorinated steroids are generally more potent
than non-fluorinated steroids, but the risk of adverse effects
such as acne, itching, atrophy, and telangiectasias increases
with the use of potent steroids. In cases where steroids are
used in addition to peeling or depigmenting agents, less po-
tent steroids should be used to minimize the side effects. Our
patients did not show any steroid-induced and treatment-
induced complications during the study period. 
In this study, the 2% LM mixed with 0.05% BV and 2%
LA yielded a better outcome. It is postulated that linoleic acid
should cause the pigmentary lightening effect in melasma
patients, because 2% LM mixed with 0.05% BV and 2% LA
was clearly superior to the 2% LM mixed with 0.05% BV.
Contrary to in vitro test results, topical lincomycin did not
have a lightening effect in melasma patients. We could not
also exclude the permissive role of these components. Patients
without a family history of melasma showed a statistically
greater improvement in the group C, but the duration, pat-
tern, and type were not significant factors. The effect of ther-
apy was characterized primarily by a progressive lightening
of the site treated, followed by a reduction of the size of the
lesion, i.e., some parts of the lesion resolved completely, while
other parts had a still discernible outline. The response rate
of more than moderate improvement (43.7%) after 6 weeks
treatment of 2% LM mixed with 0.05% BV and 2% LA was
somewhat lower than the improvement rate ranging from
65% to 73% in other reports using topical tretinoin and/or
hydroquinone (11, 21). While other reports evaluated the
efficacy during a 10-week period, this study employed a 6-
week study period. This may explain the lower response rate
in this study. The formula containing tretinoin and/or hydro-
quinone induces irritation dermatitis in many cases (22),
which hampers the use of this formula. Other investigators
have reported increased pigmentaion in Asian patients on
daily tretinoin and hydrocortisone; the increased pigmenta-
tion was presumably caused by retinoid dermatitis, with
resultant postinflammatory hyperpigmentation (17). The
formula used in this study did not show any side effects
including irritation.
In conclusion, the effect of treatment with 2% LM mixed
with 0.05% BV and 2% LA was superior to that with 2%
LM mixed with 0.05% BV in melasma patients. Topical appli-
cation of the formula containing linoleic acid in this study is
considered to be effective in the treatment of melasma patients
without apparent side effects.
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